Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 59Colorectal Neoplasms 45Rectal Neoplasms 35Stomach Neoplasms 27Pancreatic Neoplasms 27Neoplasm Metastasis 24Neoplasms 19Colonic Neoplasms 18Triple Negative Breast Neoplasms 7Esophageal Neoplasms 6Adenocarcinoma 6Liver Neoplasms 5Brain Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Head and Neck Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Unknown Primary 2Melanoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma 2Breast Neoplasms, Male 2

Interventions

Flow Cytometry 2talactoferrin alfa 1perifosine 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1alectinib 1Vorinostat 1Trastuzumab 1Tissue Array Analysis 1Taxes 1Sunitinib 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Polymerase Chain Reaction 1Paclitaxel 1Oxaliplatin 1Oligonucleotide Array Sequence Analysis 1Microarray Analysis 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Immunohistochemistry 1Immunoenzyme Techniques 1Gene Expression Profiling 1Fluorodeoxyglucose F18 1Fluorescent Antibody Technique 1Everolimus 1Electroacupuncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Salivary Gland Neoplasms × Capecitabine × Clear all
NCT00101075 2017-02-27

Title XELOX FOR SALIVARY GLAND CANCERS

Dana-Farber Cancer Institute

Phase 2 Terminated
9 enrolled
Head & Neck

Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡